Pre-clinical assessment for LRRK2 activity from accessible peripheral tissues from PD patients may be useful to minimize adverse effects from the overdose of LRRK2 inhibitor whilst maintaining efficacy in brain1. This evidence concerns the gene LRRK2 and Parkinson disease.